HUE057439T2 - Terápiás vakcina 1-es típusú cukorbetegség kezelésére gyermekekben, sejtválogató alkalmazása és eljárás TREG sejtek sokszorosítására 1-es típusú cukorbetegség kezelésére szolgáló terápiás vakcina elõállítására - Google Patents
Terápiás vakcina 1-es típusú cukorbetegség kezelésére gyermekekben, sejtválogató alkalmazása és eljárás TREG sejtek sokszorosítására 1-es típusú cukorbetegség kezelésére szolgáló terápiás vakcina elõállításáraInfo
- Publication number
- HUE057439T2 HUE057439T2 HUE13739523A HUE13739523A HUE057439T2 HU E057439 T2 HUE057439 T2 HU E057439T2 HU E13739523 A HUE13739523 A HU E13739523A HU E13739523 A HUE13739523 A HU E13739523A HU E057439 T2 HUE057439 T2 HU E057439T2
- Authority
- HU
- Hungary
- Prior art keywords
- treatment
- diabetes type
- therapeutic vaccine
- children
- multiplying
- Prior art date
Links
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title 2
- 229940021747 therapeutic vaccine Drugs 0.000 title 2
- 210000004027 cell Anatomy 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 210000003289 regulatory T cell Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL399447A PL218400B1 (pl) | 2012-06-06 | 2012-06-06 | Szczepionka do leczenia cukrzycy typu 1 u dzieci, zastosowanie sortera komórek oraz sposób namnażania komórek Treg in vitro do wytwarzania szczepionki do leczenia cukrzycy typu 1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE057439T2 true HUE057439T2 (hu) | 2022-05-28 |
Family
ID=48808489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13739523A HUE057439T2 (hu) | 2012-06-06 | 2013-06-04 | Terápiás vakcina 1-es típusú cukorbetegség kezelésére gyermekekben, sejtválogató alkalmazása és eljárás TREG sejtek sokszorosítására 1-es típusú cukorbetegség kezelésére szolgáló terápiás vakcina elõállítására |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20150165007A1 (hu) |
| EP (1) | EP2859092B1 (hu) |
| CY (1) | CY1123467T1 (hu) |
| DK (1) | DK2859092T3 (hu) |
| ES (1) | ES2807279T3 (hu) |
| HR (1) | HRP20201177T1 (hu) |
| HU (1) | HUE057439T2 (hu) |
| LT (1) | LT2859092T (hu) |
| PL (2) | PL218400B1 (hu) |
| PT (1) | PT2859092T (hu) |
| SI (1) | SI2859092T1 (hu) |
| WO (1) | WO2013184011A1 (hu) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170232084A1 (en) | 2013-04-26 | 2017-08-17 | Enzo Biochem Inc. | Immune modulation for the treatment of age-related macular degeneration |
| PL236046B1 (pl) | 2015-12-17 | 2020-11-30 | Gdanski Univ Medyczny | Sposób namnażania in vitro limfocytów T regulatorowych CD4+ FoxP3+ |
| CA3137456A1 (en) * | 2019-04-30 | 2020-11-05 | The Regents Of The University Of California | Bead-free ex-vivo expansion of human regulatory t cells |
| PL241050B1 (pl) * | 2019-12-12 | 2022-07-25 | Gdanski Univ Medyczny | Zastosowanie limfocytów T regulatorowych jako leku w leczeniu stwardnienia rozsianego |
| EP3985105A1 (en) | 2020-10-16 | 2022-04-20 | Uniwersytet Gdanski | Conditioned regulatory t cell population tregs with enhanced therapeutic potential, method for obtaining of conditioned tregs and the medical use of the tregs population |
| EP3985106A1 (en) | 2020-10-16 | 2022-04-20 | Uniwersytet Gdanski | Conditioned regulatory t cell population with enhanced therapeutic potential, method for obtaining of regulatory t cell population and the medical use of regulatory t cell population |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1798569A (zh) | 2003-06-02 | 2006-07-05 | 莫西亚药物公司 | 用于治疗1型糖尿病的治疗性疫苗组合物 |
| JP2006280307A (ja) * | 2005-04-01 | 2006-10-19 | Kyoto Univ | 制御性ｔ細胞の製造方法 |
| EP2514315A3 (en) * | 2005-08-24 | 2012-11-07 | Yeda Research and Development Co. Ltd. | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance |
| WO2007117602A2 (en) * | 2006-04-07 | 2007-10-18 | Biogen Idec Ma Inc. | Isolation and use of human regulatory t cells |
| WO2007127787A2 (en) * | 2006-04-25 | 2007-11-08 | Joslin Diabetes Center, Inc. | Insulin autoantigen-specific regulatory cd4+ t cells |
| EP2402028A1 (en) | 2010-07-01 | 2012-01-04 | Sanofi Pasteur | Enterovirus vaccines for preventing and treating type 1 diabetes (II) |
| EP2402029A1 (en) | 2010-07-01 | 2012-01-04 | Sanofi Pasteur | Enterovirus vaccines for preventing or treating type 1 diabetes (III) |
| US9481866B2 (en) * | 2011-12-16 | 2016-11-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T cell populations enriched for stable regulatory T-cells |
-
2012
- 2012-06-06 PL PL399447A patent/PL218400B1/pl unknown
-
2013
- 2013-06-04 HU HUE13739523A patent/HUE057439T2/hu unknown
- 2013-06-04 PL PL13739523T patent/PL2859092T3/pl unknown
- 2013-06-04 WO PCT/PL2013/000072 patent/WO2013184011A1/en active Application Filing
- 2013-06-04 EP EP13739523.2A patent/EP2859092B1/en active Active
- 2013-06-04 ES ES13739523T patent/ES2807279T3/es active Active
- 2013-06-04 SI SI201331762T patent/SI2859092T1/sl unknown
- 2013-06-04 PT PT137395232T patent/PT2859092T/pt unknown
- 2013-06-04 DK DK13739523.2T patent/DK2859092T3/da active
- 2013-06-04 US US14/405,906 patent/US20150165007A1/en not_active Abandoned
- 2013-06-04 LT LTEP13739523.2T patent/LT2859092T/lt unknown
-
2017
- 2017-12-22 US US15/852,227 patent/US11944672B2/en active Active
-
2019
- 2019-10-23 US US16/661,038 patent/US20200054724A1/en not_active Abandoned
-
2020
- 2020-07-28 HR HRP20201177TT patent/HRP20201177T1/hr unknown
- 2020-07-29 CY CY20201101056T patent/CY1123467T1/el unknown
-
2024
- 2024-02-27 US US18/588,535 patent/US20240197848A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11944672B2 (en) | 2024-04-02 |
| US20180117134A1 (en) | 2018-05-03 |
| US20240197848A1 (en) | 2024-06-20 |
| EP2859092A1 (en) | 2015-04-15 |
| PT2859092T (pt) | 2020-07-23 |
| PL218400B1 (pl) | 2014-11-28 |
| SI2859092T1 (sl) | 2021-02-26 |
| US20150165007A1 (en) | 2015-06-18 |
| PL2859092T3 (pl) | 2020-11-16 |
| US20200054724A1 (en) | 2020-02-20 |
| ES2807279T3 (es) | 2021-02-22 |
| LT2859092T (lt) | 2020-09-25 |
| EP2859092B1 (en) | 2020-04-29 |
| WO2013184011A1 (en) | 2013-12-12 |
| CY1123467T1 (el) | 2022-03-24 |
| DK2859092T3 (da) | 2020-07-27 |
| PL399447A1 (pl) | 2013-12-09 |
| HRP20201177T1 (hr) | 2021-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2794859A4 (en) | METHOD FOR PRODUCING NATURAL KILLER CELLS, NATURAL KILLER CELLS PRODUCED THEREFOR, AND COMPOSITION FOR TREATING CANCERS AND INFECTIOUS DISEASES CONTAINING THE SAME | |
| WO2013005053A3 (en) | Progenitor cells of mesodermal lineage | |
| JP2012140442A5 (hu) | ||
| SI2859092T1 (sl) | Terapevtsko cepivo za zdravljenje diabetesa tipa 1 pri otrocih, uporaba naprave za sortiranje celic in postopek multipliciranja TREG celic za pridobivanje terapevtskega cepiva za zdravljenje diabetesa tipa 1 | |
| PT3321355T (pt) | Métodos e composições para a derivação clínica de uma célula alogénica e utilizações terapêuticas | |
| HK1205185A1 (en) | Methods and composition related to brown adipose-like cells | |
| EP2824182A4 (en) | PROCESS FOR STIMULATING T-CELLS AND USE THEREOF | |
| WO2014008181A3 (en) | Decellularized muscle matrix | |
| EP2865666A4 (en) | HEXAHYDROPENTALENE DERIVATIVES, METHOD OF MANUFACTURE AND USE IN MEDICINE | |
| GB201220914D0 (en) | Improvements in and relating to dynamic splints | |
| EP2878666A4 (en) | INDUSTRIAL PREPARATION OF NATURAL KILLING CELLS (NKS) AND INJECTION USING HUMAN ALLOGENIC CARYOCYTES | |
| EP2745767B8 (en) | Improvements in and relating to ophthalmoscopes | |
| GB2501670B (en) | Improvements in or relating to beauty, health, or therapeutic treatments | |
| ZA201405887B (en) | Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine | |
| IL230751A0 (en) | New peptides, preparations containing them and used in methods to treat metabolic, cardiac and immune diseases | |
| GB201223184D0 (en) | Improvements in and relating to ophthalmoscopes | |
| MX351765B (es) | Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares. | |
| EP2711382A4 (en) | DIFLUOROBENZOTRIAZOLYL SOLAR CELL MATERIAL AND METHOD FOR ITS MANUFACTURE AND USE | |
| HK1212727A1 (zh) | 產生免疫調節細胞之方法、依該方法所製備之細胞及其應用 | |
| EP2850117A4 (de) | Novolak-basierte c-sn-materialien, ihre herstellung und ihre verwendung in elektrochemischen zellen | |
| EP2759556A4 (en) | DIFLUORO BENZOTRIAZOLYL POLYMER MATERIAL FOR SOLAR CELL AND METHOD FOR PREPARING AND USING SAME | |
| TJONDROPURNOMO | TOULMIN'S MODEL AND FIGURES OF SPEECH IN MARIO TEGUH GOLDEN WAYS'RHETORIC SPEECH | |
| HK1209073A1 (en) | Plod-2 stimulators and their use in the treatment of skin plod-2 | |
| IL239236B (en) | Therapeutic preparations for apoptotic cells, a method for their preparation and use | |
| TN2013000404A1 (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease |